domain of fibronectin, fibroblast growth factor, collagen and polylysine as well as functional equivalents thereof.

4. (Amended) The composition according to claim 1, wherein the function of having an affinity specific for a target cell is derived from a functional substance selected from the group consisting of proteins each having an affinity for the target cell, hormones, cytokines, anti-target cell antibodies, sugar chains, carbohydrates and cells.

5. (Amended) The composition according to claim 1, wherein the functional substance is a functional substance having an affinity specific for a target cell derived from a cell selected from the group consisting of vascular endothelial cells, inflammatory cells, hematopoietic stem cells, brain endothelial cells and bone marrow cells.

10. (Amended) The composition according to claim 8, wherein the functional substance having an affinity for a virus is a functional substance selected from the group consisting of anti-virus antibodies, heparin-II-binding domain of fibronectin, fibroblast growth factor, collagen and polylysine as well as functional equivalents thereof.

11. (Amended) The composition according to claim 8, wherein the functional substance having an affinity

specific for a target cell is a functional substance selected from the group consisting of proteins each having an affinity for the target cell, hormones, cytokines, anti-target cell antibodies, sugar chains, carbohydrates and cells.

16. (Amended) The gene therapy method according to claim 14, wherein the function of having an affinity for a virus is derived from a functional substance selected from the group consisting of anti-virus antibodies, heparin-II-binding domain of fibronectin, fibroblast growth factor, collagen and polylysine as well as functional equivalents thereof.

17. (Amended) The gene therapy method according to claim 14, wherein the function of having an affinity specific for a target cell is derived from a functional substance selected from the group consisting of proteins each having an affinity for the target cell, hormones, cytokines, anti-target cell antibodies, sugar chains, carbohydrates and cells.

18. (Amended) The gene therapy method according to claim 14, wherein the functional substance is a functional substance having an affinity specific for a target cell derived from a cell selected from the group consisting of

A3

vascular endothelial cells, inflammatory cells, hematopoietic stem cells, brain endothelial cells and bone marrow cells.

23. (Amended) The gene therapy method according to claim 21, wherein the functional substance having an affinity for a virus is a functional substance selected from the group consisting of anti-virus antibodies, heparin-II-binding domain of fibronectin, fibroblast growth factor, collagen and polylysine as well as functional equivalents thereof.

A4

24. (Amended) The gene therapy method according to claim 21, wherein the functional substance having an affinity specific for a target cell is a functional substance selected from the group consisting of proteins each having an affinity for the target cell, hormones, cytokines, anti-target cell antibodies, sugar chains, carbohydrates and cells.

Delete claims 27-39 in favor of the remaining claims.

A5

40. (Amended) The composition according to any one of claims 1 to 13, wherein the target cell is a cell selected from the group consisting of hematopoietic stem

cells, blood cells, leukocytes, lymphocytes, T cells, tumor-infiltrating lymphocytes, B cells and cancer cells.

[Please delete claim 41.]

42. (Amended) The composition according to any one of claims 1 to 13, wherein a protein encoded by the transferred gene is a therapeutic protein which is expressed upon expression of the gene in the target cell in an amount sufficient for the treatment.

43. (Amended) The composition according to claim 42, wherein the protein is an enzyme or a cytokine.

44. (Amended) The composition according to any one of claims 1 to 13, wherein the virus is a virus vector.

45. (Amended) The composition according to claim 44, wherein the virus is a retrovirus vector, an adenovirus vector, an adeno-associated virus vector or a vaccinia virus vector.

Add the following new claims:

46. (New) The gene therapy method according to any one of claims 14-26, wherein the target cell is a cell selected from the group consisting of hematopoietic stem

cells, blood cells, leukocytes, lymphocytes, T cells, tumor-infiltrating lymphocytes, B cells and cancer cells.

47. (New) The gene therapy method according to any one of claims 14-26, wherein a protein encoded by the transferred gene is a therapeutic protein which is expressed upon expression of the gene in the target cell in an amount sufficient for the treatment.

48. (New) The gene therapy method according to claim 47, wherein the protein is an enzyme or a cytokine.

49. (New) The gene therapy method according to any one of claims 14-26, wherein the virus is a virus vector.

50. (New) The gene therapy method according to claim 49, wherein the virus is a retrovirus vector, an adenovirus vector, an adeno-associated virus vector or a vaccinia virus vector.

REMARKS

The amendments made above are made to place the application in better form consistent with U.S. practice, e.g. eliminate improper multi-dependencies consistent with 37 CFR 1.75(c) in order to ensure examination of all claims, and eliminate the non-statutory "use" claims. The amendments are